Baird Capital's Strata Oncology Launches Strata Trial with First Cancer Center Partners

Baird Capital portfolio company Strata Oncology today announced the launch of Strata Trial, a nationwide observational study providing no-cost tumor sequencing and clinical trial matching for 100,000 advanced cancer patients, to study the impact of tumor sequencing on clinical trial environment. 

Read the full news release.